$CSDX CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH
https://www.globenewswire.com/news-release/20...Pharm.html
CHEYENNE, Wyo., Feb. 11, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) (“CS Group” or the “Company”), a medical technology and hygiene solutions company, today announced the appointment of Shah Teelani & Associates, a Dubai-based Public Company Accounting Oversight Board (PCAOB) registered audit firm, to consolidate and audit the Group 2025 financial statements.
Under the engagement, Shah Teelani & Associates will oversee the consolidation and audit of financial statements for:
CS Diagnostics Corp. (OTCQB: CSDX)
CS Interpharm GT LLC
CS Diagnostics Pharma GmbH
The engagement reflects the Group’s continued commitment to strengthening financial governance, regulatory compliance, and transparency as it advances its international expansion strategy across the United States, GCC region, and Europe.
Management stated that appointing a PCAOB-registered audit firm is a significant step in aligning the Group’s financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework. The consolidated audit will support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence.
The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform, international distribution expansion.
“Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company,” said Mohammad Essayed, Group Chief Financial Officer. “As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”
The Group continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.
https://www.globenewswire.com/news-release/20...Pharm.html
CHEYENNE, Wyo., Feb. 11, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) (“CS Group” or the “Company”), a medical technology and hygiene solutions company, today announced the appointment of Shah Teelani & Associates, a Dubai-based Public Company Accounting Oversight Board (PCAOB) registered audit firm, to consolidate and audit the Group 2025 financial statements.
Under the engagement, Shah Teelani & Associates will oversee the consolidation and audit of financial statements for:
CS Diagnostics Corp. (OTCQB: CSDX)
CS Interpharm GT LLC
CS Diagnostics Pharma GmbH
The engagement reflects the Group’s continued commitment to strengthening financial governance, regulatory compliance, and transparency as it advances its international expansion strategy across the United States, GCC region, and Europe.
Management stated that appointing a PCAOB-registered audit firm is a significant step in aligning the Group’s financial reporting structure with U.S. public company standards while integrating its growing international companies under a unified reporting framework. The consolidated audit will support enhanced financial clarity, streamlined reporting processes, and strengthened investor confidence.
The 2025 consolidated financial review will encompass operations related to the MEDUSA hygiene and disinfectant platform, international distribution expansion.
“Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company,” said Mohammad Essayed, Group Chief Financial Officer. “As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”
The Group continues to focus on expanding its manufacturing partnerships, regulatory positioning, international distribution agreements, and capital markets readiness as part of its broader global growth roadmap.
